Alternative analysis of the data from a HPV vaccine study in India - Authors' reply
- PMID: 34973220
- DOI: 10.1016/S1470-2045(21)00729-4
Alternative analysis of the data from a HPV vaccine study in India - Authors' reply
Conflict of interest statement
PB has received research funding from GlaxoSmithKline through the Chittaranjan National Cancer Institute (Kolkata, India) during his previous position at the institute. RM declares no competing interests. Where authors are identified as personnel of the International Agency for Research on Cancer (IARC)/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the IARC/WHO.
Comment in
-
Alternative analysis of the data from a HPV vaccine study in India.Lancet Oncol. 2022 Jan;23(1):e9. doi: 10.1016/S1470-2045(21)00661-6. Lancet Oncol. 2022. PMID: 34973236 No abstract available.
Comment on
-
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.Lancet Oncol. 2021 Nov;22(11):1518-1529. doi: 10.1016/S1470-2045(21)00453-8. Epub 2021 Oct 8. Lancet Oncol. 2021. PMID: 34634254 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical